Association of CSF α‐synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study
Alzheimer's & Dementia · 2024
DOI: 10.1002/alz.14276 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Duygu Tosun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: alpha-Synuclein, Alzheimer Disease, Amyloid beta-Peptides, Cognitive Dysfunction. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIH/NIA, Genentech, Inc.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Cerebrospinal fluid (CSF) α‐synuclein (α‐syn) seed amplification assay (SAA) is a sensitive and specific tool for detecting Lewy body co‐pathology in Alzheimer's disease. METHODS A total of 1637 cross‐sectional and 407 longitudinal CSF samples from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were tested with SAA. We examined longitudinal dynamics of amyloid beta (Aβ), α‐syn seeds, and phosphorylated tau181 (p‐tau181), along with global and domain‐specific cognition in stable SAA+, stable SAA−, and those who converted to SAA+ from SAA−. RESULTS SAA+ individuals had faster cognitive decline than SAA−, notably in mild cognitive impairment, and presented with earlier symptom onset. SAA+ conversion was associated with CSF Aβ42 positivity but did not impact the progression of either CSF Aβ42 or CSF p‐tau181 status. CSF Aβ42, p‐tau181, and α‐syn SAA were all strong predictors of clinical progression, particularly CSF Aβ42. In vitro, CSF α‐syn SAA kinetic parameters were associated with participant demographics, clinical profiles, and cognitive decline. DISCUSSION These results highlight the interplay between amyloid and α‐syn and their association with disease progression. Highlights Seed amplification assay (SAA) positivity was associated with greater cognitive decline and earlier symptom onset. Thirty‐four Alzheimer's Disease Neuroimaging Initiative (ADNI) individuals progressed from SAA− to SAA+, that is, ≈ 5% conversion. SAA conversion was associated with amyloid beta (Aβ) pathology and greater cognitive decline. SAA status did not impact the progression of either CSF Aβ42 or phosphorylated tau181 biomarkers. Change in clinical diagnosis was associated with both Alzheimer's disease biomarkers and SAA. SAA kinetic parameters were associated with clinical features and progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
- Department of Veterans Affairs Medical Center, Northern California Institute for Research and Education (NCIRE), San Francisco, California, USA.
- R&D Unit, Amprion Inc., San Diego, California, USA.
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Duygu Tosun, Pamela Thropp, Cornelis Blauwendraat
Förderung
- NIA NIH HHS
- NIH/NIA
- Genentech, Inc
- Intramural NIH HHS
Zitieren
APA
Tosun, D., Hausle, Z., Thropp, P., Concha-Marambio, L., Lamoureux, J., Lebovitz, R., Shaw, L. M., Singleton, A. B., Weiner, M. W., Alzheimer's Disease Neuroimaging Initiative, & Blauwendraat, C. (2024). Association of CSF α‐synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14276
Vancouver
Tosun D, Hausle Z, Thropp P, Concha-Marambio L, Lamoureux J, Lebovitz R, et al. Association of CSF α‐synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study. Alzheimer's & Dementia. 2024. doi:10.1002/alz.14276
BibTeX
@article{Tosun2024,
author = {Tosun, Duygu and Hausle, Zachary and Thropp, Pamela and Concha-Marambio, Luis and Lamoureux, Jennifer and Lebovitz, Russ and Shaw, Leslie M and Singleton, Andrew B and Weiner, Michael W and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative and Blauwendraat, Cornelis},
title = {Association of CSF α‐synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study},
journal = {Alzheimer's & Dementia},
year = {2024},
doi = {10.1002/alz.14276}
}
EUVIMED